{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-236377","form_type":"8-K","ticker":null,"cik":"0001764974","company_name":"Turnstone Biologics Corp.","filed_at":"2024-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.523476+00:00","generated_at":"2026-05-30T15:30:46.510279+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Turnstone cuts 60% of workforce, extends cash runway into Q2 2026; CFO and CMO leave","bullets":["Workforce reduction of ~60%; one-time severance charge of ~$2.3M expected in Q4 2024.","Cash runway extended by three quarters, now expected into Q2 2026.","Portfolio prioritized to focus on Phase 1 TIDAL-01 (Selected TIL) program; clinical update expected H1 2025.","CFO Venkat Ramanan resigns effective Oct 25; VP Finance Wendy Worcester named Principal Financial Officer.","CMO Michael Burgess retires as interim CMO but remains on board; COO Saryah Azmat promoted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-236377","json":"https://secwatch.observer/filing/0001193125-24-236377.json","markdown":"https://secwatch.observer/filing/0001193125-24-236377.md","text":"https://secwatch.observer/filing/0001193125-24-236377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764974/000119312524236377/0001193125-24-236377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764974/000119312524236377/d834511d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T15:30:46.510279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91a1926b3482ea3af4f13e5fa474a6fd5691de7a","claim":"Turnstone Biologics Corp. announced a restructuring with charges of approximately $2.3 million (approximately 60%).","evidence_excerpt":"Turnstone anticipates a one-time severance-related charge associated with the workforce reduction to be approximately $2.3 million, which represents cash expenditures related to employee severance and notice period payments, benefits and related costs that Turnstone expects to incur in connection with the workforce reduction.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764974/000119312524236377/0001193125-24-236377-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.3 million"},{"label":"Headcount","value":"approximately 60%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}